ONO-1162 Phase 3 study A placebo-controlled multicentre double-blind randomized parallel-group study in patients with chronic heart failure (J-SHIFT study)

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 10 Aug 2022

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

05 Aug 2022 Status changed from active, no longer recruiting to completed.
27 Feb 2021 Results of meta-analysis of 6 studies, published in the Clinical Cardiology.
20 Sep 2019 According to an Ono pharmaceutical media release, based on the data from SHIFT and J-SHIFT studies, In December 2018, the company has received the manufacturing and marketing approval of Corolan (Ivabradine) in Japan, for the treatment of patients with chronic heart failure with resting heart rate greater that or equal to 75 beats per minute in sinus rhythm.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com